Prosjekter finansiert av KLINBEFORSK

Prosjekter med finansiering etter utlysning av programmidler i 2016:

Prosjekttittel Søkerinstitusjon Prosjektleder Tildeling (kr)
Randomized autologous hematopoietic stem cell transplantation vs. Alemtuzumab for patients with relapsing remitting Multiple Sclerosis (RAM-MS) Helse Bergen HF Lars Bø 19 970 000
 A Phase 1b/2 clinical trial with Axl kinase inhibitor BGB324 in combination with Dabrafenib/Trametinib or Pembrolizumab in metastatic melanoma: Identification of predictive markers of response Helse Bergen HF Oddbjørn Straume 17 570 000
Acetylsalisylic acid as secondary prevention in colorectal cancer (ASAC Trial) Oslo universitetssykehus HF Bjørn Atle Bjørnbeth 13 840 000
The Norwegian Antibiotics for Pneumonia in Children (NAPiC) study Oslo universitetssykehus HF Håvard Ove Skjerven 19 320 000
A Norwegian multicentre trial assessing the effectiveness of tailoring infliximab treatment by therapeutic drug monitoring, the NOR-DRUM study Diakonhjemmet Sykehus Espen A. Haavardsholm 12 430 000
PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA-2): A randomized, placebo-controlled, multicenter Trial Akershus universitetssykehus HF Torbjørn Omland 20 000 000
 Tenecteplase in wake-up ischaemic stroke trial – TWIST Universitetssykehuset Nord-Norge HF Ellisiv B. Mathiesen 15 490 000

Prosjekter med finansiering etter utlysning av programmidler i 2017:

Prosjekttittel Søkerinstitusjon Prosjektleder Tildeling (kr)
BEta-Blocker Treatment after Acute Myocardial Infarction in revascularized patients with preserved left ventricular systolic function (BETAMI trial) Oslo universitetssykehus HF Dan Atar 19 998 270
Improved prediction of outcome by global strain and mechanical dispersion in patients with myocardial infarction, heart failure and primary prophylactic internal defibrillator. Oslo universitetssykehus HF Thor Edvardsen 15 493 000
Establishment of Molecular profiling for Individual clinical routine Treatment decisions in Early Breast Cancer (EMIT) – clinical trials Oslo universitetssykehus HF Bjørn Naume 17 568 500
BackToBasic Oslo universitetssykehus HF John-Anker Zwart 13 840 000
Innovative steroid treatment to reduce asthma development in first-time rhinovirus induced wheezing – INSTAR St. Olav’s Hospital HF Henrik Døllner 19 322 500
Immunotherapy for Hematological Malignancies – A Path to Cure St. Olav’s Hospital HF Henrik Hjorth-Hansen 12 431 000
Sphenopalatine ganglion block in chronic migraine (MIBLOCK) St. Olav’s Hospital HF Anders Mattias Linde 18 724 100
Changing the speciaist mental health care Helse Bergen HF Gerd Kvale 19 974 000